Introduction
============

Pentraxin 3 (PTX3) is an inflammatory mediator produced by a variety of tissue cells, like neutrophils, macrophages, myeloid dendritic, endothelial and epithelial cells \[[@B1]\]. During sepsis a massive inflammatory activation occurs, which often leads to an important coagulation system dysfunction. PTX3 upregulates coagulation promoters *in vitro*\[[@B2]\]. PTX3 may represent an early marker of severity and outcome and may be related to coagulation impairment in septic patients.

Methods
=======

We studied 90 patients affected by severe sepsis or septic shock previously enrolled in a prospective trial regarding the impact of glycemic control on inflammation and coagulation. At enrollment we recorded sepsis signs, plasminogen activator inhibitor 1 (PAI-1, an inhibitor of fibrinolysis) activity and concentration, prothrombin fragments 1 + 2 (F1+2) concentration (a marker of coagulation activation), disease severity and organ dysfunctions. We measured plasma PTX3 levels at enrollment and everyday until day 7. Mortality was recorded at day 90.

Results
=======

Although not different on day 1, PTX3 remained significantly higher in nonsurvivors than in survivors over the first 5 days (*P*= 0.002 by general linear model). On day 1, septic shock patients had higher PTX3 levels than patients with severe sepsis (274.41 ± 321.92 vs 114.95 ± 129.93 ng/ml, *P*= 0.029, *t*test). Day 1 PTX3 was significantly correlated with SAPS II score (*R*^2^= 0.08, *P*= 0.006, linear regression), platelets count (*R*^2^= 0.14, *P*\< 0.001) and SOFA score (*R*^2^= 0.16, *P*\< 0.001). Day 1 PTX3 was correlated with PAI-1 concentration (*R*^2^= 0.211, *P*\< 0.001) and activity (*R*^2^= 0.231, *P*\< 0.001) and with F1+2 concentration (*R*^2^= 0.09, *P*= 0.045).

Conclusions
===========

Persisting high levels of circulating PTX3 over the first days from sepsis onset may be associated with mortality. PTX3 correlates with severity of sepsis and with sepsis-associated coagulation dysfunction.
